Sign in
CompletedPhase 4

Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.

Key facts

Who runs it
Centre hospitalier universitaire de Liege
Where
Belgium1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
10 people enrolled
Started
1 Jun 2026
Ended
1 Sept 2026
Type of study
Interventional
Record updated
16 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Male and female adults between 50 and 65 years of age
  • Be healthy
  • Willingness to sign the consent form
  • Willingness to the 9 blood samples
  • Willingness to receive the 2 doses of the RHZ vaccine (at 2-6 months interval)

Who cannot take part

  • Intake of any immunosuppressive therapies
  • Contraindication for the RHZ vaccine or one or more of the constituents
  • Recent live or non-live vaccination(s) (3 months prior to inclusion)
  • Prior varicella zoster virus vaccination
  • Prior herpes zoster virus vaccination
  • History of prior episode of herpes zoster
  • Pre-menoposal women
  • Any form of immunosuppression
  • Unwillingness to sign the consent form
  • Active herpes zoster at day 0 of the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the sequential VZV-specific CMI and HMI as well as the lymphocyte typing before and after recombinant HZ vaccination, to better understand the post-vaccination transient specific VZV immunosuppression.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
16 March 2026